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Familial hypercholesterolaemia (FH) with elevated LDL cholesterol is a dominantly inherited genetic disease (or disorder) that affects 50% of first-degree relatives in FH families. FH is the genetic disease that kills most individuals in the world, and a genetic disease requires a genetic diagnosis. Brown and Goldstein received the Nobel Prize in 1985 for showing the cause of FH, including how FH can be diagnosed genetically. It therefore seems a mystery why genetic testing for FH is not used universally, and only rarely in the USA where Brown and Goldstein still work. Many European countries use genetic testing for FH, because it makes sense. Less affluent countries do not use it, because of the expense, while some rich countries including Japan and the USA do not use genetic testing for FH, because it is not yet considered 'standard of care '. We recently showed that FH is more common in the general population than originally thought:
1,2 using a clinical diagnosis, FH was found in 1:200 individuals in the Danish general population. Several later studies have confirmed that FH is common, and in The Netherlands, Poland, the UK, the USA, and Denmark FH frequencies in the general population of 1:200 to 1:250 have been observed, using either a clinical or a genetic diagnosis. [3] [4] [5] [6] [7] [8] [9] Compared with other genetic diseases found in children, FH is by far the most common. 10 Recent studies have also documented that FH is both underdiagnosed and undertreated worldwide, with the exceptions being The Netherlands and Norway. 2 In this issue of the journal, Tada and co-workers provide important data on FH in Japan, including the value of genetic diagnosis and the importance of clinical signs of FH for the prevalence of coronary heart disease. 11 3.4 (95% CI 1.0-10.9) in individuals with an FH mutation, and 11.6 (95% CI 4.4-30.2) in individuals with both clinical signs and an FH mutation, compared with individuals with high LDL cholesterol alone. Further, the presence of clinical signs and an FH mutation both contributed to a better prediction of coronary artery disease events, estimated by significant increases in area under the curve in C-statistics and by net reclassification improvement. Thus, these important findings from Japan highlight that a genetic diagnosis of FH identifies individuals at higher risk of coronary artery disease than solely judged by the LDL cholesterol level alone, probably because the genetic diagnosis indicates a lifelong effect.
A recent US study reported that an FH phenotype of LDL cholesterol > _4.9 mmol/L (> _190 mg/dL) was associated with a five-fold risk What are the pros and cons of genetic testing for FH? Pros include that an FH mutation together with high LDL cholesterol identifies individuals with lifelong high LDL cholesterol and the highest risk of coronary heart disease, i.e. those with the greatest need for cholesterol-lowering therapy. Genetic FH testing is pivotal for efficient cascade screening of families, and also identifies the 50% of family members not at risk. In addition, those with a genetic cause of high LDL cholesterol may be more motivated to adhere to the prescribed medication. Sceptics of genetic testing claim that LDL cholesterol measurements alone provide the same information as FH mutation information-this is clearly not the case. 11, 14 Further, for personal or insurance reasons, some individuals are afraid of having a genetic diagnosis; however, Wiegman and co-workers in The Netherlands have shown that if cholesterol-lowering therapy is initiated early in children with FH mutations, coronary heart disease is no longer a problem: these individuals live a healthy life like any other person. 10 How is genetic testing for FH used around the world? Figure 1 shows the number of individuals with FH in selected countries and in all major parts of the world, based on our current estimate of a frequency of FH in most countries of 1:250 in the general population. Based on these numbers and on information from experts on FH from around the world (see the Acknowledgements), we also present (i) an estimate of the fraction of individuals diagnosed with FH in 2017 ( Figure 1 As highlighted before, 2 The Netherlands and Norway lead the world in diagnosis of individuals and families with FH and essentially offer genetic testing to all suspected of having FH (Figure 1) . Genetic testing is also widespread throughout the rest of Europe; although most countries have diagnosed only a minor fraction of individuals with FH-with the exceptions, beside The Netherlands and Norway, being the UK, Spain, Denmark, Belgium, Czech Republic, Slovakia, Iceland, and Switzerland who diagnose 2-10% of those with FH and often use genetic testing. It is noteworthy that Japan and Canada are doing well in diagnosis of individuals with FH, and Canada, Australia, and New Zealand often use genetic testing. South Africa has a long tradition for FH diagnosis and use of genetic testing due to founder effects in subpopulations. However, in the rest of the world, including Russia, the USA, and most of Asia, Africa, and Latin America, both the diagnosis of FH and use of genetic testing for FH is sparse. There are exceptions, of course, such as genetic testing being used at selected places in Japan, the USA, Brazil, and Uruguay.
In conclusion, and as supported by Tada and co-workers, 11 genetic testing for FH is essential in individuals with high LDL cholesterol. This will help identify individuals at the highest risk of coronary heart disease, and is pivotal for identifying all family members with (and without) FH and high risk. FH is not a disease or disorder affecting a single patient, but a condition affecting 50% of first-degree relatives in families with FH.
